15 November 2019 - If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis in Europe.

Novartis today announced the CHMP of the EMA has adopted a positive opinion for Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity (i.e. Gd-enhancing T1 lesions or active, new or enlarging, T2 lesions). 

While progression is different for each patient and influenced by multiple factors, including use of disease-modifying treatments, it is estimated that up to 80% of patients will eventually transition from RRMS to SPMS.

Read Novartis press release